ARCHIVES

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

This article is from The Cancer Letter archive.

Vol. 31 No. 13 | April 1, 2005

Download PDF Visit The Full Archive

Related Articles

NCI To Test 5,000 DC-Area Jews To Determine Risk Of BRCA 1 Mutation

October 6, 1995

Adjuvant Nutrition Breast Cancer Study Offered To Groups

March 19, 1982

In Brief: GM Awards Recognize Levine, Levy, Roeder, Tjian; U.S. Science, Tech Medals Awarded

May 14, 1999

DCT Advisors OK 4 Contract Concepts In Therapeutics

June 28, 1991

NCAB Review Of Cancer Control Program Finds It Has Made Substantial Progress But Has Problems

October 13, 1978

Cancer Policy: New Cancer Board to Take A Year to Conduct First Study

April 18, 1997